References
- Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al.. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12):2210–21.
- Greipp PR, Miguel SanJ, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al.. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–20. Epub 2005 Apr 4. Erratum in: J Clin Oncol. 2005;23(25):6281.
- Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, et al.. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003;4(6):379–98. Review. Erratum in: Hematol J. 2004;5(3):285.
- Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3–9.
- Bird JM, Owen RG, D'Sa S, Snowden JA, Pratt G, Ashcroft J, et al.. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol. 2011;154(1):32–75.
- Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, et al.. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28(33):4976–84.
- Hutchison CA, Batuman V, Behrens J, Bridoux F, Sirac C, Dispenzieri A, et al.. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol.2011;8(1):43–51.
- Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al.. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23(36):9219–26.
- Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE, et al.. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol. 2011;12(8):743–52.
- Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, et al.. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010;376(9757):1989–99.
- Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, et al.. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009;23(10):1716–30.
- Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, et al.. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2011; doi: 10·1038/leu.2011·346. [Ahead of print].
- Johnson DC, Corthals SL, Walker BA, Ross FM, Gregory WM, Dickens NJ, et al.. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol. 2011;29(7):797–804.
- Palumbo A, Davies F, Kropff M, Bladé J, Delforge M, Costa Leal daF, et al.. Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. Ann Hematol. 2010;89(8):803–11.
- Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, Miguel SanJ, Barlogie B, et al.. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414–23.